Inhaled Insulin Manufacturers Find Size Matters After Exubera Cmte. Review
Executive Summary
Inhaled insulin manufacturers are emphasizing smaller devices and easier dosing of their products following the review of Pfizer/Sanofi-Aventis' Exubera by FDA's Endocrinologic & Metabolic Drugs Advisory Committee
You may also be interested in...
Lilly Expects Experience To Help Avoid Mistakes Of Pfizer’s Exubera Launch
Lilly's experience in the diabetes marketplace is one of the factors that fuels company optimism about its AIR inhaled insulin product, for which the company has an NDA submission goal of 2009, CEO Sidney Taurel told the Bear Stearns Healthcare Conference in New York, Sept. 11
Lilly Expects Experience To Help Avoid Mistakes Of Pfizer’s Exubera Launch
Lilly's experience in the diabetes marketplace is one of the factors that fuels company optimism about its AIR inhaled insulin product, for which the company has an NDA submission goal of 2009, CEO Sidney Taurel told the Bear Stearns Healthcare Conference in New York, Sept. 11
Abbott Expands Pharmaceutical Pipeline With $3.7 Bil Kos Acquisition
Abbott's proposed $3.7 bil. acquisition of Kos Pharmaceuticals will help diversify Abbott's existing cardiovascular franchise, and could also expand its pipeline into respiratory diseases